source
- Early Inclusion of China Boosts Global Biotech Clinical Development EfficiencyMany global biotech firms still treat China as a later-stage commercial market, adding it only after key development decisions. This practice often forces costly bridging studies, extends timelines…
- Haisco licenses inflammatory disease candidate to US startup Sentivera; ViiV's HIV drug cleared for newbornsHaisco Pharmaceutical announced that it has granted a license to US biotech Sentivera for the ex‑China rights to an unnamed inflammatory‑disease candidate. The agreement gives Sentivera the ability…